Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason M Pogue

Showing results (51-60 of 167) with videos related to

Pageof 17
Sort By:
American Journal of Infection Control|January 25, 2011
Investigating the impact of the definition of previous antibiotic exposure related to isolation of extended spectrum β-lactamase-producing Klebsiella pneumoniaeSuprat Saely, Keith S Kaye, Marilynn R Fairfax, et al.
Infectious Disease Clinics of North America|May 22, 2016
Agents of Last Resort: Polymyxin ResistanceKeith S Kaye, Jason M Pogue, Thien B Tran, et al.
The Journal of Antimicrobial Chemotherapy|April 10, 2024
Population pharmacokinetic/pharmacodynamic target attainment analysis of IV fosfomycin for the treatment of MDR Gram-negative bacterial infectionsWalaiporn Wangchinda, Jason M Pogue, Visanu Thamlikitkul, et al.
Microbiology Spectrum|May 31, 2022
A Multicenter Comparison of Carbapenem-Nonsusceptible Enterobacterales and Pseudomonas aeruginosa Rates in the US (2016 to 2020): Facility-Reported Rates versus Rates Based on Updated Clinical Laboratory and Standards Institute BreakpointsVikas Gupta, Kalvin C Yu, Jason M Pogue, et al.
Infection and Drug Resistance|September 27, 2018
Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant <i>Enterobacteriaceae</i>Lindsay A Petty, Oryan Henig, Twisha S Patel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 12, 2023
Executive Summary: State-of-the-Art Review: State of the Management of Infections Caused by Multidrug-Resistant Gram-Negative OrganismsArsheena Yassin, Mariya Huralska, Jason M Pogue, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 22, 2023
State of the Management of Infections Caused by Multidrug-Resistant Gram-Negative OrganismsArsheena Yassin, Mariya Huralska, Jason M Pogue, et al.
The Journal of Antimicrobial Chemotherapy|June 26, 2018
Ceftazidime/avibactam versus standard-of-care agents against carbapenem-resistant Enterobacteriaceae harbouring blaKPC in a one-compartment pharmacokinetic/pharmacodynamic modelKatie E Barber, Jason M Pogue, Henderson D Warnock, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 6, 2014
Carbapenem-resistance in gram-negative bacilli and intravenous minocycline: an antimicrobial stewardship approach at the Detroit Medical CenterJason M Pogue, Anupama Neelakanta, Ryan P Mynatt, et al.
Infectious Disease Clinics of North America|October 4, 2020
Agents of Last Resort: An Update on Polymyxin ResistanceQiwen Yang, Jason M Pogue, Zekun Li, et al.
Pageof 17

Showing results (51-60 of 167) with videos related to

Sort By:
Pageof 17
American Journal of Infection Control|January 25, 2011
Investigating the impact of the definition of previous antibiotic exposure related to isolation of extended spectrum β-lactamase-producing Klebsiella pneumoniaeSuprat Saely, Keith S Kaye, Marilynn R Fairfax, et al.
Infectious Disease Clinics of North America|May 22, 2016
Agents of Last Resort: Polymyxin ResistanceKeith S Kaye, Jason M Pogue, Thien B Tran, et al.
The Journal of Antimicrobial Chemotherapy|April 10, 2024
Population pharmacokinetic/pharmacodynamic target attainment analysis of IV fosfomycin for the treatment of MDR Gram-negative bacterial infectionsWalaiporn Wangchinda, Jason M Pogue, Visanu Thamlikitkul, et al.
Microbiology Spectrum|May 31, 2022
A Multicenter Comparison of Carbapenem-Nonsusceptible Enterobacterales and Pseudomonas aeruginosa Rates in the US (2016 to 2020): Facility-Reported Rates versus Rates Based on Updated Clinical Laboratory and Standards Institute BreakpointsVikas Gupta, Kalvin C Yu, Jason M Pogue, et al.
Infection and Drug Resistance|September 27, 2018
Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant <i>Enterobacteriaceae</i>Lindsay A Petty, Oryan Henig, Twisha S Patel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 12, 2023
Executive Summary: State-of-the-Art Review: State of the Management of Infections Caused by Multidrug-Resistant Gram-Negative OrganismsArsheena Yassin, Mariya Huralska, Jason M Pogue, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 22, 2023
State of the Management of Infections Caused by Multidrug-Resistant Gram-Negative OrganismsArsheena Yassin, Mariya Huralska, Jason M Pogue, et al.
The Journal of Antimicrobial Chemotherapy|June 26, 2018
Ceftazidime/avibactam versus standard-of-care agents against carbapenem-resistant Enterobacteriaceae harbouring blaKPC in a one-compartment pharmacokinetic/pharmacodynamic modelKatie E Barber, Jason M Pogue, Henderson D Warnock, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 6, 2014
Carbapenem-resistance in gram-negative bacilli and intravenous minocycline: an antimicrobial stewardship approach at the Detroit Medical CenterJason M Pogue, Anupama Neelakanta, Ryan P Mynatt, et al.
Infectious Disease Clinics of North America|October 4, 2020
Agents of Last Resort: An Update on Polymyxin ResistanceQiwen Yang, Jason M Pogue, Zekun Li, et al.
Pageof 17